AstraZeneca’s ‘Ambition Zero Carbon’ strategy to eliminate emissions by 2025 and be carbon negative across the entire value chain by 2030

The $1bn programme will include the launch of next-generation respiratory inhalers and a wide range of energy initiatives to reduce climate impact to zero

Company to join the Sustainable Markets Council to drive climate policy change and will complete a 50-million tree reforestation plan
 

AstraZeneca today unveiled an ambitious programme for zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030, bringing forward decarbonisation plans by more than a decade.

Launched today at the World Economic Forum (WEF) Annual Meeting in Davos, Switzerland, AstraZeneca’s ‘Ambition Zero Carbon’ strategy accelerates the Company’s existing science-based targets, doubling energy productivity and using renewable energy for both power and heat, as well as switching to a 100% electric vehicle fleet five years ahead of schedule.

The Company will invest up to $1bn to achieve these goals and to develop the next-generation respiratory inhalers with near-zero Global Warming Potential (GWP) propellants. ‘Ambition Zero Carbon’ sets out to make AstraZeneca’s global operations responsible for zero carbon emissions without relying on offset schemes to reach zero emissions on aggregate.

Also included in today’s plan, is ‘AZ Forest’, a 50-million tree reforestation initiative that will be rolled out over the next five years. In partnership with local governments and One Tree Planted, a non-profit organisation focused on global reforestation, the first trees will go into the ground in Australia in February 2020, with France, Indonesia and other countries to follow. This initiative supports WEF’s newly launched ‘1T.org – The Champions for a Trillion Trees’ platform.

As a further step to help shape policy and find cross-industry solutions to rapidly decarbonise the global economy, Pascal Soriot, Chief Executive Officer, will also participate in the inaugural meeting of the Sustainable Markets Council (SMC). The Council was established by His Royal Highness, the Prince of Wales, with the support of WEF, as an advisory body of public-private-philanthropic leaders to drive sustainable solutions in line with the United Nation’s Sustainable Development Goals.

Mr. Soriot, said: “Climate change is an urgent threat to public health, the environment and the sustainability of the global economy. Since 2015, we have reduced our carbon emissions from operations by almost a third and our water consumption by almost one fifth.

But now is the time to act even faster and redouble our efforts. The commitments AstraZeneca has made today as part of our ‘Ambition Zero Carbon’ strategy will enable us to speed up the reduction of our Company’s impact on climate and inspire collaboration at a global level to effect policy change.”

Alexander Farsan,  Global Lead of Science Based Targets, WWF International and Steering Committee member of the Science Based Targets initiative, said: “We congratulate AstraZeneca for responding to the climate emergency and raising the ambition of their science-based targets, which were already in line with the Paris Agreement’s most ambitious goal – to limit warming to 1.5 degrees. As the impact of climate change is felt by more and more communities across the globe, AstraZeneca’s collaborative approach to scale the impact of a science-based approach across their value chain is exactly what is needed.”  

‘Ambition Zero Carbon’ strategy

Ambition Zero Carbon’ significantly accelerates a plan developed in 2015 to reduce AstraZeneca’s carbon footprint, with targets verified in line with the science of climate change. In order to achieve zero carbon by 2025, AstraZeneca will convert 100% of its energy consumption to renewable sources for both power and heat, and have a 100% electric vehicle fleet.

Carbon negative value chain

By recognising that the total emissions from its value chain partners is significantly larger than its own direct operations, AstraZeneca is pledging to engage its suppliers to reduce their direct emissions through to 2030 and identify carbon removal options that will lead to more carbon dioxide (CO2) removed from the atmosphere than added to it. This will result in AstraZeneca becoming carbon negative across its entire value chain by 2030.

Next-generation inhalers

AstraZeneca commits to launching its next-generation inhaler to treat asthma and chronic obstructive pulmonary disease (COPD) with near-zero GWP propellants by 2025. AstraZeneca expects the propellant used in the next generation pressurised metered-dose inhalers (pMDI) to have a GWP that is 90-99% lower than propellants used in older pMDIs. In addition to offering next-generation pMDIs, AstraZeneca will continue offering dry powder inhaled (DPI) medicines. pMDIs are an important therapeutic option for patients, particularly where familiarity with the device, limited lung function, young or advanced age or reduced dexterity or cognition are considerations.

‘AZ Forest’

Alongside its work to eliminate carbon emissions from its own operations, AstraZeneca also recognises the direct link between reforestation and the impact it can have on both the climate and human health. Trees naturally remove CO2 and are essential to mitigate the effects of climate change. AstraZeneca will partner with recognised reforestation organisations and governments in a number of countries to plant 50 million trees over the next five years, the first programmes will start in February 2020.

Sustainable Markets Council

With the support of the World Economic Forum, His Royal Highness, The Prince of Wales, created the SMC to accelerate a transition to sustainable markets and a decarbonised global economy. AstraZeneca is a founding member of this public-private network of global leaders which helps to explore game-changing solutions and champion a movement towards sustainable market creation. The SMC will be officially launched in Davos and will come together to discuss concrete approaches to achieving its ambition for 2020.

Indices and rankings

CDP A List for Climate Change
On 20 January 2020, AstraZeneca was commended for its climate action, achieving a place on global environmental impact non-profit CDP's prestigious ‘A List’ for climate change, based on the Company’s climate reporting in 2019, for the fourth consecutive year. AstraZeneca was recognised for its actions to cut emissions, mitigate climate risks and develop the low-carbon economy, based on the data submitted by the company through CDP’s 2019 climate change questionnaire. The Company is one of a small number of high-performing companies out of thousands that were scored.

Corporate Knights World’s 100 Most Sustainable Corporations
On 21 January 2020, AstraZeneca was also recognised by Corporate Knights as one of the world’s 100 most sustainable companies out of more than 7,000 companies assessed, ranking 56th overall and 2nd in biopharmaceuticals.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

Media Relations

 

 

Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Angela Fiorin

BioPharmaceuticals

+44 1223 344 690

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

     

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals
(Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals
(Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

Other medicines

+44 203 749 5631

Craig Marks

Finance

Fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access

Retail investors

+44 203 749 5824

US toll-free

 

+1 866 381 72 77

 

tags

  • Corporate and financial
  • Sustainability